Infinity Gets More Than A Cash Boost With AbbVie Tie-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
In a deal worth more than $800 million, AbbVie injects a vote of confidence into Infinity’s late-stage PI3K inhibitor program, but leaves the biotech the freedom to conduct other partnerships.